December 7, 2011
English version of the "Kyowa Hakko Kirin Group CSR Report 2011" has been issued
Tokyo, Japan, December 7, 2011 --- Kyowa Hakko Kirin Co., Ltd. ("Kyowa Hakko Kirin") issued the English version of the "Kyowa Hakko Kirin Group CSR (Corporate Social Responsibility) Report 2011" on November 30 and published this report on the company website (http://www.kyowa-kirin.com/responsibility/csr_report/index.html). This report describes the efforts of the group, who provides society with beneficial values through corporate activities in order to achieve the Corporate Philosophy of Kyowa Hakko Kirin Group.
Main contents of "Kyowa Hakko Kirin Group CSR Report 2011"
We introduce the thoughts of employees on their work from the group companies in the world.
|1.||For Patients the World Over (Kyowa Hakko Kirin, Kyowa Medex)
We develop innovative new pharmaceutical products with the aim of delivering medicine to as many patients around the world as early as possible.
|2.||For Human Health (Kyowa Hakko Bio)
We contribute to human health through our technology, such as the manufacture of amino acids by fermentation methods.
Introduction of CSR activities by stakeholder:
In order to gain a strong trust from our stakeholders, and to become an earnest corporate group who contributes to society, we introduce here the activities for stakeholders of various categories: customers, employees, shareholders and investors, society, and the global environment. At the end of the volume, we have also published the opinions we have received from various third parties.
Our effort for the global environment:
We will introduce our efforts in consideration of the environment, safety, and health conducted for the active protection of the global environment, which will be inherited by the next generation. This covers the whole cycle of products from research and development, manufacture, distribution, and use to disposal.
Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.